Search

Your search keyword '"Glisson, Bonnie S."' showing total 659 results
Start Over Author "Glisson, Bonnie S."
659 results on '"Glisson, Bonnie S."'

2. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Author

Cascone, Tina, Leung, Cheuk H., Weissferdt, Annikka, Pataer, Apar, Carter, Brett W., Godoy, Myrna C. B., Feldman, Hope, William, Jr, William N., Xi, Yuanxin, Basu, Sreyashi, Sun, Jing Jing, Yadav, Shalini S., Rojas Alvarez, Frank R., Lee, Younghee, Mishra, Aditya K., Chen, Lili, Pradhan, Monika, Guo, Haiping, Sinjab, Ansam, Zhou, Nicolas, Negrao, Marcelo V., Le, Xiuning, Gay, Carl M., Tsao, Anne S., Byers, Lauren Averett, Altan, Mehmet, Glisson, Bonnie S., Fossella, Frank V., Elamin, Yasir Y., Blumenschein, Jr, George, Zhang, Jianjun, Skoulidis, Ferdinandos, Wu, Jia, Mehran, Reza J., Rice, David C., Walsh, Garrett L., Hofstetter, Wayne L., Rajaram, Ravi, Antonoff, Mara B., Fujimoto, Junya, Solis, Luisa M., Parra, Edwin R., Haymaker, Cara, Wistuba, Ignacio I., Swisher, Stephen G., Vaporciyan, Ara A., Lin, Heather Y., Wang, Jing, Gibbons, Don L., Jack Lee, J., Ajami, Nadim J., Wargo, Jennifer A., Allison, James P., Sharma, Padmanee, Kadara, Humam, Heymach, John V., and Sepesi, Boris

Published
2023
Full Text
View/download PDF

4. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single‐arm phase 2 clinical trial

Author

Gold, Kathryn A, Kies, Merrill S, William, William N, Johnson, Faye M, Lee, J Jack, and Glisson, Bonnie S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Rare Diseases, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, Disease Progression, ErbB Receptors, Erlotinib Hydrochloride, Feasibility Studies, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Protein Kinase Inhibitors, Response Evaluation Criteria in Solid Tumors, Skin Neoplasms, squamous cell carcinoma, skin cancer, erlotinib, epidermal growth factor receptor, anti-neoplastic agents, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BACKGROUND:Cutaneous squamous cell carcinoma (CSCC) is a very common malignancy in which most patients present with localized disease. Recurrent and metastatic disease is rare, and there is no standard therapy. These tumors frequently overexpress the epidermal growth factor receptor (EGFR). We conducted a phase 2 trial to determine the response rate to therapy with erlotinib, an EGFR tyrosine kinase inhibitor, in patients with locoregionally recurrent or metastatic CSCC that was not amenable to curative treatment (NCT01198028). METHODS:Eligible patients had CSCC not amenable to curative intent therapy. Patients who had previously received anti-EGFR targeted therapy were excluded. All patients received oral therapy with erlotinib 150 mg daily. Response was assessed every 8 weeks, and treatment continued until progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was overall response rate according to RECIST 1.1 criteria. RESULTS:A total of 39 patients received treatment during the trial; 29 of these patients were evaluable for response. The overall response rate was 10% (3/29); all responses were partial responses. The disease control rate (partial response + stable disease) was 72% (21/29). The median progression-free survival was 4.7 months (95% confidence interval, 3.5-6.2 months); the median overall survival was 13 months (95% confidence interval, 8.4-20.5 months). No unexpected toxicities were seen. CONCLUSION:Erlotinib therapy was feasible for most patients with incurable CSCC and was associated with expected toxicities. However, only a modest response rate of 10% was observed. Further study of EGFR tyrosine kinase inhibitors in this patient population is not warranted. Cancer 2018;124:2169-73. © 2018 American Cancer Society.

Published
2018

5. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors

Author

Ferrarotto, Renata, Mitani, Yoshitsugu, Diao, Lixia, Guijarro, Irene, Wang, Jing, Zweidler-McKay, Patrick, Bell, Diana, William, William N, Glisson, Bonnie S, Wick, Michael J, Kapoun, Ann M, Patnaik, Amita, Eckhardt, Gail, Munster, Pamela, Faoro, Leonardo, Dupont, Jakob, Lee, J Jack, Futreal, Andrew, El-Naggar, Adel K, and Heymach, John V

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Pediatric Cancer, Digestive Diseases, Rare Diseases, Clinical Research, Pediatric, Dental/Oral and Craniofacial Disease, Genetics, Aetiology, 2.1 Biological and endogenous factors, Adult, Aged, Animals, Antineoplastic Agents, Biomarkers, Tumor, Bone Neoplasms, Carcinoma, Adenoid Cystic, DNA Mutational Analysis, Disease-Free Survival, Female, Genetic Predisposition to Disease, HEK293 Cells, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Liver Neoplasms, Male, Mice, Nude, Middle Aged, Molecular Targeted Therapy, Mutation, Phenotype, Predictive Value of Tests, Proportional Hazards Models, Receptor, Notch1, Retrospective Studies, Risk Factors, Salivary Gland Neoplasms, Time Factors, Transfection, Treatment Outcome, Xenograft Model Antitumor Assays, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Purpose Adenoid cystic carcinomas (ACCs) represent a heterogeneous group of chemotherapy refractory tumors, with a subset demonstrating an aggressive phenotype. We investigated the molecular underpinnings of this phenotype and assessed the Notch1 pathway as a potential therapeutic target. Methods We genotyped 102 ACCs that had available pathologic and clinical data. Notch1 activation was assessed by immunohistochemistry for Notch1 intracellular domain. Luciferase reporter assays were used to confirm Notch1 target gene expression in vitro. The Notch1 inhibitor brontictuzumab was tested in patient-derived xenografts from patients with ACC and in a patient with ACC who was enrolled in a phase I study. Results NOTCH1 mutations occurred predominantly (14 of 15 patients) in the negative regulatory region and Pro-Glu-Ser-Thr-rich domains, the same two hotspots seen in T-cell acute lymphoblastic leukemias, and led to pathway activation in vitro. NOTCH1-mutant tumors demonstrated significantly higher levels of Notch1 pathway activation than wild-type tumors on the basis of Notch1 intracellular domain staining ( P = .004). NOTCH1 mutations define a distinct aggressive ACC subgroup with a significantly higher likelihood of solid subtype ( P < .001), advanced-stage disease at diagnosis ( P = .02), higher rate of liver and bone metastasis ( P ≤ .02), shorter relapse-free survival (median, 13 v 34 months; P = .01), and shorter overall survival (median 30 v 122 months; P = .001) when compared with NOTCH1 wild-type tumors. Significant tumor growth inhibition with brontictuzumab was observed exclusively in the ACC patient-derived xenograft model that harbored a NOTCH1 activating mutation. Furthermore, an index patient with NOTCH1-mutant ACC had a partial response to brontictuzumab. Conclusion NOTCH1 mutations define a distinct disease phenotype characterized by solid histology, liver and bone metastasis, poor prognosis, and potential responsiveness to Notch1 inhibitors. Clinical studies targeting Notch1 in a genotype-defined ACC subgroup are warranted.

Published
2017

7. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Author

Hong, Lingzhi, Negrao, Marcelo V., Dibaj, Seyedeh S., Chen, Runzhe, Reuben, Alexandre, Bohac, Jadi M., Liu, Xiaoke, Skoulidis, Ferdinandos, Gay, Carl M., Cascone, Tina, Mitchell, Kyle G., Tran, Hai T., Le, Xiuning, Byers, Lauren A., Sepesi, Boris, Altan, Mehmet, Elamin, Yasir Y., Fossella, Frank V., Kurie, Jonathan M., Lu, Charles, Mott, Frank E., Tsao, Anne S., Rinsurongkawong, Waree, Lewis, Jeff, Gibbons, Don L., Glisson, Bonnie S., Blumenschein, George R., Jr., Roarty, Emily B., Futreal, P. Andrew, Wistuba, Ignacio I., Roth, Jack A., Swisher, Stephen G., Papadimitrakopoulou, Vassiliki A., Heymach, John V., Lee, J. Jack, Simon, George R., and Zhang, Jianjun

Published
2020
Full Text
View/download PDF

9. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Author

Cascone, Tina, William, Jr, William N., Weissferdt, Annikka, Leung, Cheuk H., Lin, Heather Y., Pataer, Apar, Godoy, Myrna C. B., Carter, Brett W., Federico, Lorenzo, Reuben, Alexandre, Khan, Md Abdul Wadud, Dejima, Hitoshi, Francisco-Cruz, Alejandro, Parra, Edwin R., Solis, Luisa M., Fujimoto, Junya, Tran, Hai T., Kalhor, Neda, Fossella, Frank V., Mott, Frank E., Tsao, Anne S., Blumenschein, Jr, George, Le, Xiuning, Zhang, Jianjun, Skoulidis, Ferdinandos, Kurie, Jonathan M., Altan, Mehmet, Lu, Charles, Glisson, Bonnie S., Byers, Lauren Averett, Elamin, Yasir Y., Mehran, Reza J., Rice, David C., Walsh, Garrett L., Hofstetter, Wayne L., Roth, Jack A., Antonoff, Mara B., Kadara, Humam, Haymaker, Cara, Bernatchez, Chantale, Ajami, Nadim J., Jenq, Robert R., Sharma, Padmanee, Allison, James P., Futreal, Andrew, Wargo, Jennifer A., Wistuba, Ignacio I., Swisher, Stephen G., Lee, J. Jack, Gibbons, Don L., Vaporciyan, Ara A., Heymach, John V., and Sepesi, Boris

Published
2021
Full Text
View/download PDF

10. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

Author

Liu, Xiaochun, Kambrick, Susan, Fu, Siqing, Naing, Aung, Subbiah, Vivek, Blumenschein, George R, Glisson, Bonnie S, Kies, Merrill S, Tsimberidou, Apostolia M, Wheler, Jennifer J, Zinner, Ralph G, Hong, David S, Kurzrock, Razelle, and Piha-Paul, Sarina A

Subjects
Rare Diseases, Clinical Research, Dental/Oral and Craniofacial Disease, Cancer, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Cetuximab, Female, Follow-Up Studies, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms, Prognosis, Sirolimus, Survival Rate, solid tumors, bevacizumab, cetuximab, temsirolimus, Oncology and Carcinogenesis
Abstract

BackgroundBevacizumab and temsirolimus are active agents in advanced solid tumors. Temsirolimus inhibits mTOR in the PI3 kinase/AKT/mTOR pathway as well as CYP2A, which may be a resistance mechanism for cetuximab. In addition, temsirolimus attenuates upregulation of HIF-1α levels, which may be a resistance mechanism for bevacizumab.Patients and methodsWe analyzed safety and responses in 21 patients with advanced solid tumors treated with bevacizumab, cetuximab, and temsirolimus.ResultsThe median age of patients was 60 years (range, 23-80 years). The median number of prior systemic therapies was 3 (range, 1-6). The maximum tolerated dose (MTD) was determined to be bevacizumab 10 mg/kg biweekly, temsirolimus 5 mg weekly and cetuximab 100/75 mg/m2 weekly. Grade 3 or 4 toxicities were seen in 52% of patients with the highest prevalence being hyperglycemia (14%) and hypophosphatemia (14%). Eighteen of the 21 patients were evaluable for response. Three patients were taken off the study before restaging for toxicities. Partial response (PR) was observed in 2/18 patients (11%) and stable disease (SD) lasting ≥ 6 months was observed in 4/18 patients (22%) (total = 6/18 (33%)). In 8 evaluable patients with squamous cell carcinoma of the head and neck (HNSCC) there were partial responses in 2/8 (25%) patients and SD ≥ 6 months in 1/8 (13%) patients (total = 3/8, (38%)).ConclusionThe combination of bevacizumab, cetuximab, and temsirolimus showed activity in HNSCC; however, there were numerous toxicities reported, which will require careful management for future clinical development.

Published
2016

11. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer

Author

Negrao, Marcelo V., Lam, Vincent K., Reuben, Alexandre, Rubin, Maria Laura, Landry, Lara Lacerda, Roarty, Emily B., Rinsurongkawong, Waree, Lewis, Jeff, Roth, Jack A., Swisher, Stephen G., Gibbons, Don L., Wistuba, Ignacio I., Papadimitrakopoulou, Vassiliki, Glisson, Bonnie S., Blumenschein, George R., Jr., Lee, J. Jack, Heymach, John V., and Zhang, Jianjun

Published
2019
Full Text
View/download PDF

13. Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

Author

Tran, Hai T., Lam, Vincent K., Elamin, Yasir Y., Hong, Lingzhi, Colen, Rivka, Elshafeey, Nabil A., Hassan, Islam S. A., Altan, Mehmet, Blumenschein, George R., Rinsurongkawong, Waree, Rivera, Melvin J., Vasquez, Mayra E., Carter, Brett W., Byers, Lauren E., Tsao, Anne S., Gibbons, Don L., Fossella, Frank, Glisson, Bonnie S., Zhang, Jianjun, and Heymach, John V.

Published
2021
Full Text
View/download PDF

14. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Author

Rudin, Charles M, Pietanza, M Catherine, Bauer, Todd M, Ready, Neal, Morgensztern, Daniel, Glisson, Bonnie S, Byers, Lauren A, Johnson, Melissa L, Burris, Howard A, III, Robert, Francisco, Han, Tae H, Bheddah, Sheila, Theiss, Noah, Watson, Sky, Mathur, Deepan, Vennapusa, Bharathi, Zayed, Hany, Lally, Satwant, Strickland, Donald K, Govindan, Ramaswamy, Dylla, Scott J, Peng, Stanford L, and Spigel, David R

Published
2017
Full Text
View/download PDF

16. Supplementary Methods from Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets

Author

Ferrarotto, Renata, primary, Mitani, Yoshitsugu, primary, McGrail, Daniel J., primary, Li, Kaiyi, primary, Karpinets, Tatiana V., primary, Bell, Diana, primary, Frank, Steven J., primary, Song, Xingzhi, primary, Kupferman, Michael E., primary, Liu, Bin, primary, Lee, J. Jack, primary, Glisson, Bonnie S., primary, Zhang, Jianhua, primary, Aster, Jon C., primary, Lin, Shiaw-Yih, primary, Futreal, P. Andrew, primary, Heymach, John V., primary, and El-Naggar, Adel K., primary

Published
2023
Full Text
View/download PDF

17. Data from Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets

Author

Ferrarotto, Renata, primary, Mitani, Yoshitsugu, primary, McGrail, Daniel J., primary, Li, Kaiyi, primary, Karpinets, Tatiana V., primary, Bell, Diana, primary, Frank, Steven J., primary, Song, Xingzhi, primary, Kupferman, Michael E., primary, Liu, Bin, primary, Lee, J. Jack, primary, Glisson, Bonnie S., primary, Zhang, Jianhua, primary, Aster, Jon C., primary, Lin, Shiaw-Yih, primary, Futreal, P. Andrew, primary, Heymach, John V., primary, and El-Naggar, Adel K., primary

Published
2023
Full Text
View/download PDF

18. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma

Author

Ferrarotto, Renata, primary, Sousa, Luana G., additional, Feng, Lei, additional, Mott, Frank, additional, Blumenschein, George, additional, Altan, Mehmet, additional, Bell, Diana, additional, Bonini, Flavia, additional, Li, Kaiyi, additional, Marques-Piubelli, Mario L., additional, Dal Lago, Eduardo A., additional, Johnson, Jason J., additional, Mitani, Yoshitsugu, additional, Godoy, Myrna, additional, Lee, Anna, additional, Kupferman, Michael, additional, Hanna, Ehab, additional, Glisson, Bonnie S., additional, Elamin, Yasir, additional, and El-Naggar, Adel, additional

Published
2023
Full Text
View/download PDF

19. Abstract CT218: A phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas

Author

Gay, Carl M., primary, Stewart, C. Allison, additional, Frumovitz, Michael, additional, Fujimoto, Junya, additional, xi, Yuann, additional, Wang, Qi, additional, Wang, Runsheng, additional, Novegil, Veronica, additional, Altan, Mehmet, additional, Cascone, Tina, additional, Dasari, Arvind, additional, Elamin, Yasir Y., additional, Fossella, Frank V., additional, Glisson, Bonnie S., additional, Lu, Charles S., additional, Negrao, Marcelo V., additional, Skoulidis, Ferdinandos, additional, Vokes, Natalie, additional, Cardnell, Robert J., additional, Wistuba, Ignacio I., additional, Wang, Jing, additional, Heymach, John V., additional, and Byers, Lauren A., additional

Published
2023
Full Text
View/download PDF

20. Data from Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

Author

Sen, Triparna, primary, Rodriguez, B. Leticia, primary, Chen, Limo, primary, Corte, Carminia M. Della, primary, Morikawa, Naoto, primary, Fujimoto, Junya, primary, Cristea, Sandra, primary, Nguyen, Thuyen, primary, Diao, Lixia, primary, Li, Lerong, primary, Fan, Youhong, primary, Yang, Yongbin, primary, Wang, Jing, primary, Glisson, Bonnie S., primary, Wistuba, Ignacio I., primary, Sage, Julien, primary, Heymach, John V., primary, Gibbons, Don L., primary, and Byers, Lauren A., primary

Published
2023
Full Text
View/download PDF

21. Supplementary figure 4 from A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

Author

Mazumdar, Tuhina, primary, Byers, Lauren A., primary, Ng, Patrick Kwok Shing, primary, Mills, Gordon B., primary, Peng, Shaohua, primary, Diao, Lixia, primary, Fan, You-Hong, primary, Stemke-Hale, Katherine, primary, Heymach, John V., primary, Myers, Jeffrey N., primary, Glisson, Bonnie S., primary, and Johnson, Faye M., primary

Published
2023
Full Text
View/download PDF

22. Supplementary figure 3 from A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

Author

Mazumdar, Tuhina, primary, Byers, Lauren A., primary, Ng, Patrick Kwok Shing, primary, Mills, Gordon B., primary, Peng, Shaohua, primary, Diao, Lixia, primary, Fan, You-Hong, primary, Stemke-Hale, Katherine, primary, Heymach, John V., primary, Myers, Jeffrey N., primary, Glisson, Bonnie S., primary, and Johnson, Faye M., primary

Published
2023
Full Text
View/download PDF

23. Supplementary figure 2 from A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

Author

Mazumdar, Tuhina, primary, Byers, Lauren A., primary, Ng, Patrick Kwok Shing, primary, Mills, Gordon B., primary, Peng, Shaohua, primary, Diao, Lixia, primary, Fan, You-Hong, primary, Stemke-Hale, Katherine, primary, Heymach, John V., primary, Myers, Jeffrey N., primary, Glisson, Bonnie S., primary, and Johnson, Faye M., primary

Published
2023
Full Text
View/download PDF

24. Data from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Author

Byers, Lauren Averett, primary, Wang, Jing, primary, Nilsson, Monique B., primary, Fujimoto, Junya, primary, Saintigny, Pierre, primary, Yordy, John, primary, Giri, Uma, primary, Peyton, Michael, primary, Fan, You Hong, primary, Diao, Lixia, primary, Masrorpour, Fatemeh, primary, Shen, Li, primary, Liu, Wenbin, primary, Duchemann, Boris, primary, Tumula, Praveen, primary, Bhardwaj, Vikas, primary, Welsh, James, primary, Weber, Stephanie, primary, Glisson, Bonnie S., primary, Kalhor, Neda, primary, Wistuba, Ignacio I., primary, Girard, Luc, primary, Lippman, Scott M., primary, Mills, Gordon B., primary, Coombes, Kevin R., primary, Weinstein, John N., primary, Minna, John D., primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

25. Supplementary figure 1 from A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

Author

Mazumdar, Tuhina, primary, Byers, Lauren A., primary, Ng, Patrick Kwok Shing, primary, Mills, Gordon B., primary, Peng, Shaohua, primary, Diao, Lixia, primary, Fan, You-Hong, primary, Stemke-Hale, Katherine, primary, Heymach, John V., primary, Myers, Jeffrey N., primary, Glisson, Bonnie S., primary, and Johnson, Faye M., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Tables and Methods from A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

Author

Mazumdar, Tuhina, primary, Byers, Lauren A., primary, Ng, Patrick Kwok Shing, primary, Mills, Gordon B., primary, Peng, Shaohua, primary, Diao, Lixia, primary, Fan, You-Hong, primary, Stemke-Hale, Katherine, primary, Heymach, John V., primary, Myers, Jeffrey N., primary, Glisson, Bonnie S., primary, and Johnson, Faye M., primary

Published
2023
Full Text
View/download PDF

27. Supplementary figure 5 from A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

Author

Mazumdar, Tuhina, primary, Byers, Lauren A., primary, Ng, Patrick Kwok Shing, primary, Mills, Gordon B., primary, Peng, Shaohua, primary, Diao, Lixia, primary, Fan, You-Hong, primary, Stemke-Hale, Katherine, primary, Heymach, John V., primary, Myers, Jeffrey N., primary, Glisson, Bonnie S., primary, and Johnson, Faye M., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table 5 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Author

Byers, Lauren Averett, primary, Wang, Jing, primary, Nilsson, Monique B., primary, Fujimoto, Junya, primary, Saintigny, Pierre, primary, Yordy, John, primary, Giri, Uma, primary, Peyton, Michael, primary, Fan, You Hong, primary, Diao, Lixia, primary, Masrorpour, Fatemeh, primary, Shen, Li, primary, Liu, Wenbin, primary, Duchemann, Boris, primary, Tumula, Praveen, primary, Bhardwaj, Vikas, primary, Welsh, James, primary, Weber, Stephanie, primary, Glisson, Bonnie S., primary, Kalhor, Neda, primary, Wistuba, Ignacio I., primary, Girard, Luc, primary, Lippman, Scott M., primary, Mills, Gordon B., primary, Coombes, Kevin R., primary, Weinstein, John N., primary, Minna, John D., primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

29. Data from A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

Author

Mazumdar, Tuhina, primary, Byers, Lauren A., primary, Ng, Patrick Kwok Shing, primary, Mills, Gordon B., primary, Peng, Shaohua, primary, Diao, Lixia, primary, Fan, You-Hong, primary, Stemke-Hale, Katherine, primary, Heymach, John V., primary, Myers, Jeffrey N., primary, Glisson, Bonnie S., primary, and Johnson, Faye M., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Author

Byers, Lauren Averett, primary, Wang, Jing, primary, Nilsson, Monique B., primary, Fujimoto, Junya, primary, Saintigny, Pierre, primary, Yordy, John, primary, Giri, Uma, primary, Peyton, Michael, primary, Fan, You Hong, primary, Diao, Lixia, primary, Masrorpour, Fatemeh, primary, Shen, Li, primary, Liu, Wenbin, primary, Duchemann, Boris, primary, Tumula, Praveen, primary, Bhardwaj, Vikas, primary, Welsh, James, primary, Weber, Stephanie, primary, Glisson, Bonnie S., primary, Kalhor, Neda, primary, Wistuba, Ignacio I., primary, Girard, Luc, primary, Lippman, Scott M., primary, Mills, Gordon B., primary, Coombes, Kevin R., primary, Weinstein, John N., primary, Minna, John D., primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Table 6 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Author

Byers, Lauren Averett, primary, Wang, Jing, primary, Nilsson, Monique B., primary, Fujimoto, Junya, primary, Saintigny, Pierre, primary, Yordy, John, primary, Giri, Uma, primary, Peyton, Michael, primary, Fan, You Hong, primary, Diao, Lixia, primary, Masrorpour, Fatemeh, primary, Shen, Li, primary, Liu, Wenbin, primary, Duchemann, Boris, primary, Tumula, Praveen, primary, Bhardwaj, Vikas, primary, Welsh, James, primary, Weber, Stephanie, primary, Glisson, Bonnie S., primary, Kalhor, Neda, primary, Wistuba, Ignacio I., primary, Girard, Luc, primary, Lippman, Scott M., primary, Mills, Gordon B., primary, Coombes, Kevin R., primary, Weinstein, John N., primary, Minna, John D., primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Author

Byers, Lauren Averett, primary, Wang, Jing, primary, Nilsson, Monique B., primary, Fujimoto, Junya, primary, Saintigny, Pierre, primary, Yordy, John, primary, Giri, Uma, primary, Peyton, Michael, primary, Fan, You Hong, primary, Diao, Lixia, primary, Masrorpour, Fatemeh, primary, Shen, Li, primary, Liu, Wenbin, primary, Duchemann, Boris, primary, Tumula, Praveen, primary, Bhardwaj, Vikas, primary, Welsh, James, primary, Weber, Stephanie, primary, Glisson, Bonnie S., primary, Kalhor, Neda, primary, Wistuba, Ignacio I., primary, Girard, Luc, primary, Lippman, Scott M., primary, Mills, Gordon B., primary, Coombes, Kevin R., primary, Weinstein, John N., primary, Minna, John D., primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Author

Byers, Lauren Averett, primary, Wang, Jing, primary, Nilsson, Monique B., primary, Fujimoto, Junya, primary, Saintigny, Pierre, primary, Yordy, John, primary, Giri, Uma, primary, Peyton, Michael, primary, Fan, You Hong, primary, Diao, Lixia, primary, Masrorpour, Fatemeh, primary, Shen, Li, primary, Liu, Wenbin, primary, Duchemann, Boris, primary, Tumula, Praveen, primary, Bhardwaj, Vikas, primary, Welsh, James, primary, Weber, Stephanie, primary, Glisson, Bonnie S., primary, Kalhor, Neda, primary, Wistuba, Ignacio I., primary, Girard, Luc, primary, Lippman, Scott M., primary, Mills, Gordon B., primary, Coombes, Kevin R., primary, Weinstein, John N., primary, Minna, John D., primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Author

Byers, Lauren Averett, primary, Wang, Jing, primary, Nilsson, Monique B., primary, Fujimoto, Junya, primary, Saintigny, Pierre, primary, Yordy, John, primary, Giri, Uma, primary, Peyton, Michael, primary, Fan, You Hong, primary, Diao, Lixia, primary, Masrorpour, Fatemeh, primary, Shen, Li, primary, Liu, Wenbin, primary, Duchemann, Boris, primary, Tumula, Praveen, primary, Bhardwaj, Vikas, primary, Welsh, James, primary, Weber, Stephanie, primary, Glisson, Bonnie S., primary, Kalhor, Neda, primary, Wistuba, Ignacio I., primary, Girard, Luc, primary, Lippman, Scott M., primary, Mills, Gordon B., primary, Coombes, Kevin R., primary, Weinstein, John N., primary, Minna, John D., primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Methods and Figure Legend from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Author

Byers, Lauren Averett, primary, Wang, Jing, primary, Nilsson, Monique B., primary, Fujimoto, Junya, primary, Saintigny, Pierre, primary, Yordy, John, primary, Giri, Uma, primary, Peyton, Michael, primary, Fan, You Hong, primary, Diao, Lixia, primary, Masrorpour, Fatemeh, primary, Shen, Li, primary, Liu, Wenbin, primary, Duchemann, Boris, primary, Tumula, Praveen, primary, Bhardwaj, Vikas, primary, Welsh, James, primary, Weber, Stephanie, primary, Glisson, Bonnie S., primary, Kalhor, Neda, primary, Wistuba, Ignacio I., primary, Girard, Luc, primary, Lippman, Scott M., primary, Mills, Gordon B., primary, Coombes, Kevin R., primary, Weinstein, John N., primary, Minna, John D., primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Author

Byers, Lauren Averett, primary, Wang, Jing, primary, Nilsson, Monique B., primary, Fujimoto, Junya, primary, Saintigny, Pierre, primary, Yordy, John, primary, Giri, Uma, primary, Peyton, Michael, primary, Fan, You Hong, primary, Diao, Lixia, primary, Masrorpour, Fatemeh, primary, Shen, Li, primary, Liu, Wenbin, primary, Duchemann, Boris, primary, Tumula, Praveen, primary, Bhardwaj, Vikas, primary, Welsh, James, primary, Weber, Stephanie, primary, Glisson, Bonnie S., primary, Kalhor, Neda, primary, Wistuba, Ignacio I., primary, Girard, Luc, primary, Lippman, Scott M., primary, Mills, Gordon B., primary, Coombes, Kevin R., primary, Weinstein, John N., primary, Minna, John D., primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Table 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Author

Byers, Lauren Averett, primary, Wang, Jing, primary, Nilsson, Monique B., primary, Fujimoto, Junya, primary, Saintigny, Pierre, primary, Yordy, John, primary, Giri, Uma, primary, Peyton, Michael, primary, Fan, You Hong, primary, Diao, Lixia, primary, Masrorpour, Fatemeh, primary, Shen, Li, primary, Liu, Wenbin, primary, Duchemann, Boris, primary, Tumula, Praveen, primary, Bhardwaj, Vikas, primary, Welsh, James, primary, Weber, Stephanie, primary, Glisson, Bonnie S., primary, Kalhor, Neda, primary, Wistuba, Ignacio I., primary, Girard, Luc, primary, Lippman, Scott M., primary, Mills, Gordon B., primary, Coombes, Kevin R., primary, Weinstein, John N., primary, Minna, John D., primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Materials from Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

Author

Sen, Triparna, primary, Rodriguez, B. Leticia, primary, Chen, Limo, primary, Corte, Carminia M. Della, primary, Morikawa, Naoto, primary, Fujimoto, Junya, primary, Cristea, Sandra, primary, Nguyen, Thuyen, primary, Diao, Lixia, primary, Li, Lerong, primary, Fan, Youhong, primary, Yang, Yongbin, primary, Wang, Jing, primary, Glisson, Bonnie S., primary, Wistuba, Ignacio I., primary, Sage, Julien, primary, Heymach, John V., primary, Gibbons, Don L., primary, and Byers, Lauren A., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Author

Byers, Lauren Averett, primary, Wang, Jing, primary, Nilsson, Monique B., primary, Fujimoto, Junya, primary, Saintigny, Pierre, primary, Yordy, John, primary, Giri, Uma, primary, Peyton, Michael, primary, Fan, You Hong, primary, Diao, Lixia, primary, Masrorpour, Fatemeh, primary, Shen, Li, primary, Liu, Wenbin, primary, Duchemann, Boris, primary, Tumula, Praveen, primary, Bhardwaj, Vikas, primary, Welsh, James, primary, Weber, Stephanie, primary, Glisson, Bonnie S., primary, Kalhor, Neda, primary, Wistuba, Ignacio I., primary, Girard, Luc, primary, Lippman, Scott M., primary, Mills, Gordon B., primary, Coombes, Kevin R., primary, Weinstein, John N., primary, Minna, John D., primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Author

Byers, Lauren Averett, primary, Wang, Jing, primary, Nilsson, Monique B., primary, Fujimoto, Junya, primary, Saintigny, Pierre, primary, Yordy, John, primary, Giri, Uma, primary, Peyton, Michael, primary, Fan, You Hong, primary, Diao, Lixia, primary, Masrorpour, Fatemeh, primary, Shen, Li, primary, Liu, Wenbin, primary, Duchemann, Boris, primary, Tumula, Praveen, primary, Bhardwaj, Vikas, primary, Welsh, James, primary, Weber, Stephanie, primary, Glisson, Bonnie S., primary, Kalhor, Neda, primary, Wistuba, Ignacio I., primary, Girard, Luc, primary, Lippman, Scott M., primary, Mills, Gordon B., primary, Coombes, Kevin R., primary, Weinstein, John N., primary, Minna, John D., primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table from Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck

Author

Ferrarotto, Renata, primary, Amit, Moran, primary, Nagarajan, Priyadharsini, primary, Rubin, M. Laura, primary, Yuan, Ying, primary, Bell, Diana, primary, El-Naggar, Adel K., primary, Johnson, Jason M., primary, Morrison, William H., primary, Rosenthal, David I., primary, Glisson, Bonnie S., primary, Johnson, Faye M., primary, Lu, Charles, primary, Mott, Frank E., primary, Esmaeli, Bita, primary, Diaz, Eduardo M., primary, Gidley, Paul W., primary, Goepfert, Ryan P., primary, Lewis, Carol M., primary, Weber, Randal S., primary, Wargo, Jennifer A., primary, Basu, Sreyashi, primary, Duan, Fei, primary, Yadav, Shalini S., primary, Sharma, Padmanee, primary, Allison, James P., primary, Myers, Jeffrey N., primary, and Gross, Neil D., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Data from Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets

Author

Ferrarotto, Renata, primary, Mitani, Yoshitsugu, primary, McGrail, Daniel J., primary, Li, Kaiyi, primary, Karpinets, Tatiana V., primary, Bell, Diana, primary, Frank, Steven J., primary, Song, Xingzhi, primary, Kupferman, Michael E., primary, Liu, Bin, primary, Lee, J. Jack, primary, Glisson, Bonnie S., primary, Zhang, Jianhua, primary, Aster, Jon C., primary, Lin, Shiaw-Yih, primary, Futreal, P. Andrew, primary, Heymach, John V., primary, and El-Naggar, Adel K., primary

Published
2023
Full Text
View/download PDF

44. Supplemental Figure 1 from Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer

Author

Ferrarotto, Renata, primary, Goonatilake, Ruchitha, primary, Young Yoo, Suk, primary, Tong, Pan, primary, Giri, Uma, primary, Peng, Shaohua, primary, Minna, John, primary, Girard, Luc, primary, Wang, Yuehong, primary, Wang, Liguang, primary, Li, Lerong, primary, Diao, Lixia, primary, Peng, David H., primary, Gibbons, Don L., primary, Glisson, Bonnie S., primary, Heymach, John V., primary, Wang, Jing, primary, Byers, Lauren A., primary, and Johnson, Faye M., primary

Published
2023
Full Text
View/download PDF

45. Supplemental Figure 4 from Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer

Author

Ferrarotto, Renata, primary, Goonatilake, Ruchitha, primary, Young Yoo, Suk, primary, Tong, Pan, primary, Giri, Uma, primary, Peng, Shaohua, primary, Minna, John, primary, Girard, Luc, primary, Wang, Yuehong, primary, Wang, Liguang, primary, Li, Lerong, primary, Diao, Lixia, primary, Peng, David H., primary, Gibbons, Don L., primary, Glisson, Bonnie S., primary, Heymach, John V., primary, Wang, Jing, primary, Byers, Lauren A., primary, and Johnson, Faye M., primary

Published
2023
Full Text
View/download PDF

46. Supplemental Figure 3 from Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer

Author

Ferrarotto, Renata, primary, Goonatilake, Ruchitha, primary, Young Yoo, Suk, primary, Tong, Pan, primary, Giri, Uma, primary, Peng, Shaohua, primary, Minna, John, primary, Girard, Luc, primary, Wang, Yuehong, primary, Wang, Liguang, primary, Li, Lerong, primary, Diao, Lixia, primary, Peng, David H., primary, Gibbons, Don L., primary, Glisson, Bonnie S., primary, Heymach, John V., primary, Wang, Jing, primary, Byers, Lauren A., primary, and Johnson, Faye M., primary

Published
2023
Full Text
View/download PDF

47. Supplementary tables from CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib

Author

Sen, Triparna, primary, Tong, Pan, primary, Stewart, C. Allison, primary, Cristea, Sandra, primary, Valliani, Aly, primary, Shames, David S., primary, Redwood, Abena B., primary, Fan, You Hong, primary, Li, Lerong, primary, Glisson, Bonnie S., primary, Minna, John D., primary, Sage, Julien, primary, Gibbons, Don L., primary, Piwnica-Worms, Helen, primary, Heymach, John V., primary, Wang, Jing, primary, and Byers, Lauren Averett, primary

Published
2023
Full Text
View/download PDF

48. Data from CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib

Author

Sen, Triparna, primary, Tong, Pan, primary, Stewart, C. Allison, primary, Cristea, Sandra, primary, Valliani, Aly, primary, Shames, David S., primary, Redwood, Abena B., primary, Fan, You Hong, primary, Li, Lerong, primary, Glisson, Bonnie S., primary, Minna, John D., primary, Sage, Julien, primary, Gibbons, Don L., primary, Piwnica-Worms, Helen, primary, Heymach, John V., primary, Wang, Jing, primary, and Byers, Lauren Averett, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure from Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck

Author

Ferrarotto, Renata, primary, Amit, Moran, primary, Nagarajan, Priyadharsini, primary, Rubin, M. Laura, primary, Yuan, Ying, primary, Bell, Diana, primary, El-Naggar, Adel K., primary, Johnson, Jason M., primary, Morrison, William H., primary, Rosenthal, David I., primary, Glisson, Bonnie S., primary, Johnson, Faye M., primary, Lu, Charles, primary, Mott, Frank E., primary, Esmaeli, Bita, primary, Diaz, Eduardo M., primary, Gidley, Paul W., primary, Goepfert, Ryan P., primary, Lewis, Carol M., primary, Weber, Randal S., primary, Wargo, Jennifer A., primary, Basu, Sreyashi, primary, Duan, Fei, primary, Yadav, Shalini S., primary, Sharma, Padmanee, primary, Allison, James P., primary, Myers, Jeffrey N., primary, and Gross, Neil D., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results